Study: Hormone therapy may not protect against Alzheimer's disease

February 15, 2017

MINNEAPOLIS - The latest study on hormone therapy and Alzheimer's disease shows no relationship between taking the drugs and whether you may develop the disease years later. Some previous studies have shown that hormone therapy may increase the risk of the disease, while others have shown that it may reduce the risk. The new study was published in the February 15, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"While women still need to talk to their doctors about the risks and benefits of taking hormone therapy during menopause, this study did not provide strong evidence that taking hormone therapy can protect women from Alzheimer's disease," said study author Bushra Imtiaz, MD, MPH, of the University of Eastern Finland in Kuopio.

For the study, all women age 47 to 56 living in Kuopio Province in Finland received questionnaires in the mail every five years from 1989 until 2009. Information on hormone therapy use was provided by women and also available from a Finnish registry starting in 1995. Diagnoses of Alzheimer's disease were based on a registry.

Of the 8,195 women who were followed for the full 20-year study, 4,401 reported using hormone therapy. A total of 227 women developed Alzheimer's disease during the study.

Use of hormone therapy after menopause was not associated with Alzheimer's disease risk. This was true when researchers looked at both the information the women reported themselves and the information from the registry.

When researchers looked only at the women who reported that they had used hormone therapy for more than 10 years, they found a reduced risk of Alzheimer's disease compared to women who did not use hormone therapy. However, the result was not as strong when researchers looked at hormone use and any type of dementia. When researchers looked at women who used hormone therapy for more than 10 years based on the registry data, they did not find any reduced risk of Alzheimer's disease. Imtiaz said one explanation for the different results could be the different time period for self-reported data and registry data.

Imtiaz said limitations of the study are that some information was self-reported by participants, who may not recall information accurately and that researchers could not control the results for people who had a genetic predisposition to Alzheimer's disease.
-end-
To learn more about Alzheimer's disease, visit http://www.aan.com/patients.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube.

Media Contacts: Renee Tessman, rtessman@aan.com, (612) 928-6137
Michelle Uher, muher@aan.com, (612) 928-6120

American Academy of Neurology

Related Hormone Therapy Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

Prolonged use of hormone therapy may minimize muscle loss associated with aging
Skeletal muscle mass and strength are critical in helping prevent falls, fractures, and disability.

Reducing the side-effects of prostate hormone therapy with exercise
A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research.

Hormone therapy associated with improved cognition
Estrogen has a significant role in overall brain health and cognitive function.

Why do estradiol levels vary among women using hormone therapy?
CLEVELAND, Ohio (September 24, 2019)--The benefits of hormone therapy (HT) on atherosclerosis relates to achieved estradiol levels among those women who initiate HT early in postmenopause.

Hormone therapy linked to decrease level of diabetes biomarkers
The Women's Health Initiative (WHI) remains one of the most highly quoted when debating the benefits and risks of hormone therapy.

Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Hormone therapy may be best defense against knee osteoarthritis
There is an ongoing debate regarding the relationship between knee osteoarthritis and hormone therapy (HT), with small-scale studies providing mixed results.

Hormone therapy for 'low T' may not be safe for all men
Boosting testosterone levels with hormone supplements may not be safe or appropriate for all men with low testosterone (low T), according to new research.

Artery hardening and thickness not affected by stopping hormone therapy
Heart disease is still the number one killer of US women, and hormone therapy remains a top treatment for menopause symptoms.

Read More: Hormone Therapy News and Hormone Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.